Quick Takeaways: Why It Matters? Elanco’s $120M expansion of its Elwood, Kansas site quadruples monoclonal antibody capacity and adds upstream/downstream processing, a pilot plant and QC lab, directly supporting its new biologics franchise (Befrena&nbs...
Quick Takeaways Why It Matters? Befrena gives Elanco a direct challenger to Zoetis’ Cytopoint in the fast‑growing canine allergy biologics market, with a slightly longer recommended dosing interval (every 6–8 weeks vs 4–8 weeks) and no age or weight limits...
